Exenatide and rare adverse events.
Ahmad
Syed R
SR
Swann
Joslyn
J
D000328:Adult; D000368:Aged; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008116:Lizards; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced*; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use; D014688:Venoms / Q000009:adverse effects* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide